$LQDA: Two Patent Claims Cut Liquidia in Half. The Remedy Ruling Lands Within a Week

On Tuesday morning, Liquidia Corporation (Nasdaq: LQDA) was a $6.5 billion launch story: its inhaled dry-powder treprostinil, YUTREPIA, had booked $170.4 million in sales in its fourth full quarter on the market, the company had just printed $74.7 million of quarterly net income, and the stock had closed Monday at $73.67. By Wednesday's close it was a $2.7 billion company. A single ruling out of the U.S. District Court in Delaware, finding that two claims of a United Therapeutics patent are valid and that Liquidia infringed them, took the stock from a $70.69 Tuesday close to $30.26, a 57% drop on 22.9 million shares, more than twenty times normal volume. The selling has continued into Thursday, with shares trading near $25.

The claims at issue cover the treatment of pulmonary hypertension associated with interstitial lung disease, PH-ILD, with inhaled treprostinil. That is one of YUTREPIA's two approved indications, and the one with the faster growth. The patent, U.S. No. 11,826,327, does not expire until February 2042. United Therapeutics (Nasdaq: UTHR), whose competing Tyvaso DPI did $326.6 million in the second quarter, has asked the court for injunctive relief that would restrict YUTREPIA's availability. Its stock jumped 12.5% to $541.89 on the news.

Here is what makes this a live situation rather than a closed one: the court did not decide the remedy. It ordered both sides to submit proposed judgments within one week of the September 30 ruling, which puts the next binary date around October 7. The outcomes on the table range from YUTREPIA losing the PH-ILD line on its label while continuing to sell freely into pulmonary arterial hypertension, to broader restrictions on the product's availability. Liquidia says it will appeal, and it has beaten this same opponent at the Federal Circuit before, on a nearly identical patent.

There is also history here that the one-day headlines compress away. This is not the first United Therapeutics patent aimed at YUTREPIA's PH-ILD indication. It is the second. The first one died, all claims invalidated, a result the Supreme Court declined to disturb in 2024. The company that won that fight is the same one that just lost this round at the district-court level, and appellate review is where this story has historically turned.

Get the next briefing free in your inbox before the market prices it in: Join AlphaBriefing

So the question the market is now pricing with a cleaver rather than a scalpel: what is Liquidia worth if PH-ILD goes away, what is it worth if the court goes further than a label carve-out, and what is it worth if the Federal Circuit does in 2027 or 2028 what it did in 2023? The revenue math, the damages overhang, the remedy mechanics, and the zone-by-zone breakdown are below.